- Home
- APM vs NCNA Comparison
APM vs NCNA Comparison
Compare APM & NCNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | APM | NCNA |
|---|---|---|
| Founded | 2010 | 1997 |
| Country | United Kingdom | United Kingdom |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.3M | 7.7M |
| IPO Year | 2018 | 2017 |
Fundamental Metrics
Financial Performance| Metric | APM | NCNA |
|---|---|---|
| Price | $0.84 | $2.01 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 21.7K | ★ 30.7K |
| Earning Date | 03-31-2026 | 06-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.65 | $0.03 |
| 52 Week High | $4.47 | $10.00 |
Technical Indicators
Market Signals| Indicator | APM | NCNA |
|---|---|---|
| Relative Strength Index (RSI) | 41.99 | 48.02 |
| Support Level | $0.75 | $1.83 |
| Resistance Level | $0.86 | $2.27 |
| Average True Range (ATR) | 0.06 | 0.17 |
| MACD | -0.00 | -0.01 |
| Stochastic Oscillator | 14.93 | 35.44 |
Price Performance
Historical ComparisonAbout APM Aptorum Group Limited
Aptorum Group Ltd clinical-stage biopharmaceutical company. It is engaged in the discovery, development, and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Aptorum's project pipeline includes SACT-1, a repurposed drug for the treatment of neuroblastoma, and ALS-4, a small molecule for the treatment of bacterial infections caused by Staphylococcus aureus, including but not limited to Methicillin-resistant Staphylococcus aureus (MRSA). Substantially all of the company's revenues are derived from within Hong Kong.
About NCNA NuCana plc
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States and the United Kingdom.